---
title: 'Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic
  stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results
  from a randomised, phase 3 trial'
date: '2024-02-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38302221/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240202170634&v=2.18.0
source: heidelberg[Affiliation]
description: 'BACKGROUND: The aim of this trial was to investigate the addition of
  the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and
  dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide
  maintenance treatment in transplant-eligible patients with newly diagnosed multiple
  ...'
disable_comments: true
---
BACKGROUND: The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple ...